Event
Conference
ISPOR Summit - New Approaches to Value Assessment: Towards More Informed Pricing in Healthcare
RegisterGrand Hyatt Washington
Value-based pricing has become a popular term for how healthcare pricing, particularly drug pricing, might be approached. However, what constitutes value is very much up for debate, especially when concerns about fostering innovation are factored in. This Summit will explore and debate both standard and more recently proposed approaches to measuring value and how they could be used in pricing and coverage decisions. Because value is often related to whose perspective is taken and what the decision context is, the role of patient, health plan, societal, manufacturer, and other perspectives will be considered. This Summit complements the recently published work of ISPOR’s Special Task Force on US Value Assessment Frameworks by creating a forum for discussion of its research agenda along with other current initiatives. It will involve a broad range of stakeholders, with a focus on how pricing can better reflect the value that patients and society derive from healthcare.
View the detailed agenda here: https://www.ispor.org/conferences-education/conferences/upcoming-confere...
Speakers
- Anirban Basu, PhD, University of Washington, Bothell, WA, USA
- Nancy Berg, ISPOR CEO, ISPOR, Lawrenceville, NJ, USA
- J. Jaime Caro, MDCM, Evidera, Boston, MA, USA
- Rick Chapman, PhD, MS, ICER, Boston, MA, USA
- Patricia Danzon, PhD, University of Pennsylvania, Philadelphia, PA, USA
- Nancy Devlin, PhD, Office of Health Economics, London, UK
- Robert DuBois, MD, National Pharmaceutical Council, Washington, DC, USA
- Lou Garrison, PhD, University of Washington, Seattle, WA, USA
- Patrick Gleason, PharmD, Prime Therapeutics, Eagan, MN, USA
- Susan Griffin, PhD, University of York, York, UK
- Jeroen Jansen, PhD, The Innovation and Value Initiative, Los Angeles, CA, USA
- Reed Johnson, PhD, Duke University, Durham, NC, USA
- Bryan Luce, PhD, Evidera (for the PhRMA Foundation), Seattle, WA, USA
- Mark McClellan, MD, PhD, Duke-Margolis Health Policy Center, Washington, DC, USA
- Newell McElwee, PharmD, MSPH, Boehringer-Ingelheim, CT, USA
- John M. O'Brien, PharmD, MPH US Department of Health & Human Services, Washington DC, USA
- Dan Ollendorf, PhD, Center for the Education of Value and Risk in Health, Tufts Medical Center, Boston, MA, USA
- Charles Phelps, PhD, University of Rochester, Rochester, NY, USA
- Lowell Schnipper, MD, American Society of Clinical Oncology
- Suzanne Schrandt, JD, Arthritis Foundation, Washington, DC, USA
- Joshua Seidman, PhD, MHS, Avalere, Washington DC, USA
- Liz Spurgin, MBA, Medical Device Innovation Consortium, Washington, DC, USA
- Adrian Towse, MA, Office of Health Economics, London, UK